A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes.

[1]  Ian R. White,et al.  Network Meta-analysis , 2015 .

[2]  Georgia Salanti,et al.  Directed acyclic graphs can help understand bias in indirect and mixed treatment comparisons. , 2012, Journal of clinical epidemiology.

[3]  P. Stone,et al.  Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. , 2012, The Lancet. Oncology.

[4]  M. Fallon,et al.  Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. , 2011, The journal of supportive oncology.

[5]  L. Radbruch,et al.  Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. , 2011, European journal of pain.

[6]  K. Mystakidou,et al.  Fentanyl nasal spray for the treatment of cancer pain , 2011, Expert opinion on pharmacotherapy.

[7]  Joseph C Cappelleri,et al.  Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  David C Hoaglin,et al.  Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[9]  J. Jakobsson,et al.  An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  F. Elsner,et al.  Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. , 2011, Journal of pain and symptom management.

[11]  P. Dobkin,et al.  Fear of Pain in Patients With Advanced Cancer or in Patients With Chronic Noncancer Pain , 2011, The Clinical journal of pain.

[12]  P. C. van de Kerkhof,et al.  Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris , 2011, Current medical research and opinion.

[13]  Allen W. Burton,et al.  A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain , 2010, PAIN®.

[14]  J. Jansen,et al.  Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer , 2010, Current medical research and opinion.

[15]  A. Finn,et al.  Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  T. Hayes,et al.  Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain , 2009, Current medical research and opinion.

[17]  L. Radbruch,et al.  A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial , 2009, Current medical research and opinion.

[18]  M. Fallon,et al.  29LBA Efficacy, safety and patient acceptability of fentanyl pectin nasal spray compared with immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain: a multicentre, double-blind, double-dummy, multiple-crossover study , 2009 .

[19]  S. Kaasa,et al.  Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. , 2009, Clinical therapeutics.

[20]  C. Reid,et al.  The management of cancer‐related breakthrough pain: Recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland , 2009, European journal of pain.

[21]  J. Geddes,et al.  Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis , 2009, The Lancet.

[22]  Jeroen P Jansen,et al.  Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[23]  A. Abernethy,et al.  A health economic model of breakthrough pain. , 2008, The American journal of managed care.

[24]  N. Slatkin,et al.  Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. , 2007, The journal of supportive oncology.

[25]  D. Schrijvers.  Pain control in cancer: recent findings and trends. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  L. Tremmel,et al.  A Randomized, Placebo-controlled Study of Fentanyl Buccal Tablet for Breakthrough Pain in Opioid-treated Patients With Cancer , 2006, The Clinical journal of pain.

[27]  Nicola J Cooper,et al.  Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. , 2006, Archives of internal medicine.

[28]  G. Zeppetella,et al.  Opioids for the management of breakthrough (episodic) pain in cancer patients. , 2006, The Cochrane database of systematic reviews.

[29]  Deborah M Caldwell,et al.  Simultaneous comparison of multiple treatments: combining direct and indirect evidence , 2005, BMJ : British Medical Journal.

[30]  S. Fishman,et al.  Consensus panel recommendations for the assessment and management of breakthrough pain parr I assessment , 2005 .

[31]  F. Burzotta,et al.  Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent-controlled trials. , 2005, International journal of cardiology.

[32]  G. Lu,et al.  Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.

[33]  E. Zecca,et al.  Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey , 2004, Palliative medicine.

[34]  Thomas Lumley,et al.  Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. , 2003, JAMA.

[35]  J. Farrar,et al.  Clinically important changes in acute pain outcome measures: a validation study. , 2003, Journal of pain and symptom management.

[36]  Bradley P. Carlin,et al.  Bayesian measures of model complexity and fit , 2002 .

[37]  M. Nabal,et al.  Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. , 2002, Journal of pain and symptom management.

[38]  S. Kaasa,et al.  Episodic (breakthrough) pain , 2002, Cancer.

[39]  R. Portenoy,et al.  A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. , 2002, The journal of pain : official journal of the American Pain Society.

[40]  R. Portenoy,et al.  Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®) , 2001, Pain.

[41]  Jesse A. Berlin,et al.  Defining the clinically important difference in pain outcome measures , 2000, PAIN.

[42]  S. Reddy,et al.  Breakthrough pain in cancer patients: New therapeutic approaches to an old challenge , 2000, Current review of pain.

[43]  B. Ferrell,et al.  Use of routine and breakthrough analgesia in home care. , 1999, Oncology nursing forum.

[44]  M. Simmonds.  Management of breakthrough pain due to cancer. , 1999, Oncology.

[45]  Paul Jacobsen,et al.  Breakthrough pain: characteristics and impact in patients with cancer pain , 1999, Pain.

[46]  R. Portenoy,et al.  Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study , 1999, PAIN.

[47]  R. Moore,et al.  Peak plasma concentrations after oral morphine: a systematic review. , 1998, Journal of pain and symptom management.

[48]  M. Simmonds,et al.  Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Farrar,et al.  Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. , 1998, Journal of the National Cancer Institute.

[50]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[51]  M. Ashburn,et al.  Absorption and bioavailability of oral transmucosal fentanyl citrate. , 1991, Anesthesiology.

[52]  R. Portenoy,et al.  Breakthrough pain: definition, prevalence and characteristics , 1990, Pain.

[53]  S. Kaasa,et al.  Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. , 2010, Journal of opioid management.

[54]  P. Robertson,et al.  Absorption of Fentanyl from Fentanyl Buccal Tablet in Cancer Patients With or Without Oral Mucositis , 2007, Clinical drug investigation.

[55]  J. Ashley,et al.  Description and predictors of direct and indirect costs of pain reported by cancer patients. , 2003, Journal of pain and symptom management.

[56]  David J. Spiegelhalter,et al.  WinBUGS user manual version 1.4 , 2003 .